(Total Views: 319)
Posted On: 07/24/2019 1:04:11 PM
Post# of 72446
News: $IPIX Innovation Pharma Makes Savvy Move in Partnering with Alfasigma for New IBD Drug
- GBI Research forecast the GI therapeutics market will reach $48.4 billion by 2022 - Major pharma, Alfasigma licensed IPIX's Brilacidin as a new drug for IBDs ulcerative proctitis and ulcerative proctosigmoiditis for $24 million in upfront and future milestone payments + 6% royaltie...
Got this from Innovation Pharma Makes Savvy Move in Partnering with Alfasigma for New IBD Drug
https://marketwirenews.com/news-releases/inno...8613.html/
original post by whytestocks
Go IPIX!!!
- GBI Research forecast the GI therapeutics market will reach $48.4 billion by 2022 - Major pharma, Alfasigma licensed IPIX's Brilacidin as a new drug for IBDs ulcerative proctitis and ulcerative proctosigmoiditis for $24 million in upfront and future milestone payments + 6% royaltie...
Got this from Innovation Pharma Makes Savvy Move in Partnering with Alfasigma for New IBD Drug
https://marketwirenews.com/news-releases/inno...8613.html/
original post by whytestocks
Go IPIX!!!
(3)
(0)
